Elevance Health (ELV) to Release Quarterly Earnings on Thursday

Elevance Health (NYSE:ELV) is projected to issue its quarterly earnings data before the market opens on Thursday, January 23rd. Analysts expect the company to announce earnings of $3.80 per share and revenue of $44,633,169.71 billion for the quarter. Investors interested in listening to the company’s conference call can do so using this link.

Elevance Health Trading Up 1.1 %

ELV stock opened at $389.45 on Wednesday. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.50 and a quick ratio of 1.50. Elevance Health has a 1-year low of $362.21 and a 1-year high of $567.26. The business has a 50 day simple moving average of $387.20 and a two-hundred day simple moving average of $465.15. The company has a market capitalization of $90.32 billion, a price-to-earnings ratio of 14.20, a PEG ratio of 1.09 and a beta of 0.84.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on ELV shares. Argus downgraded Elevance Health from a “buy” rating to a “hold” rating in a research report on Friday, October 18th. Mizuho lowered their price objective on shares of Elevance Health from $585.00 to $505.00 and set an “outperform” rating for the company in a research report on Tuesday, November 5th. Truist Financial reduced their target price on shares of Elevance Health from $520.00 to $480.00 and set a “buy” rating on the stock in a report on Monday, January 6th. Wells Fargo & Company lowered their price target on shares of Elevance Health from $593.00 to $495.00 and set an “overweight” rating for the company in a report on Monday, November 4th. Finally, Barclays reduced their price objective on Elevance Health from $622.00 to $501.00 and set an “overweight” rating on the stock in a research note on Tuesday, October 22nd. One analyst has rated the stock with a sell rating, two have issued a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Elevance Health currently has an average rating of “Moderate Buy” and an average target price of $536.53.

Elevance Health Company Profile

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.